Abstract | BACKGROUND: AIMS: METHODS: After approval from the Institutional Review Board and obtaining informed written consent from parents, we reviewed the anesthetic charts of nine patients who underwent 58 Nusinersen injections over a 23-month period from February 2017 to December 2018. An individualized anesthetic plan was formulated based on the patient's disease severity, anxiety level, and comfort of parents as well as the provider performing the procedure. Patients underwent intrathecal Nusinersen injection under fluoroscopic guidance, with either general anesthesia, monitored anesthesia care with medications or monitored anesthesia care without medications. Patients recovered in the postanesthesia care unit for a minimum of 1 hour after injection, irrespective of the anesthetic method utilized. Analysis included patient demographics, anesthesia type relative to spinal muscular atrophy type I vs. II, and postanesthesia recovery. RESULTS: CONCLUSION: The anesthetic plan for Nusinersen injections must be individualized to the patient's specific needs and clinical manifestations of the disease. When carefully tailored to each patient, anesthetic care is safe and successful.
|
Authors | Lauren D Brollier, Maria Matuszczak, Tejaswi Marri, Jael G Carbajal, Andrew T Moorman, Emad M Sorial, Ranu Jain |
Journal | Paediatric anaesthesia
(Paediatr Anaesth)
Vol. 31
Issue 2
Pg. 160-166
(02 2021)
ISSN: 1460-9592 [Electronic] France |
PMID | 32623818
(Publication Type: Journal Article)
|
Copyright | © 2020 John Wiley & Sons Ltd. |
Chemical References |
- Anesthetics
- Oligonucleotides
- nusinersen
|
Topics |
- Anesthesia, General
- Anesthetics
(therapeutic use)
- Child
- Humans
- Injections, Spinal
- Muscular Atrophy, Spinal
(drug therapy)
- Oligonucleotides
- Retrospective Studies
|